Compare · MDLN vs WST
MDLN vs WST
Side-by-side comparison of Medline Inc. (MDLN) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.52B, about 1.8x WST ($29.10B).
- Over the past year, MDLN is down 3.9% and WST is up 59.0% - WST leads by 63.0 points.
- MDLN has been more active in the news (13 items in the past 4 weeks vs 6 for WST).
- MDLN has more recent analyst coverage (25 ratings vs 20 for WST).
- Company
- Medline Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $51.52B
- $29.10B
- 1M return
- +8.89%
- +8.80%
- 1Y return
- -3.93%
- +59.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 13
- 6
- Recent ratings
- 25
- 20
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MDLN
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
- SEC Form SCHEDULE 13G filed by Medline Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest WST
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- West to Participate in Upcoming Investor Conference
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Reports Third-Quarter 2026 Results
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Declares Quarterly Dividend
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea